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Abstract 
7-Arylhydroxymethyltriazolopyridines 3a-c and 4a-d were synthesized by regioselective 
lithiation of [1,2,3]triazolo[1,5-a]pyridines 1 and 2 and subsequent trapping of the 7-lithio-
derivatives formed using aryl aldehydes as electrophiles. The structural relationship between 
compounds 3a-c and 4a-d and arylethanolamines suggested their consideration as potential 
cardiovascular agents. A preliminary evaluation as vascular smooth muscle relaxants was carried 
out. These compounds did not act as α1-adrenoceptor antagonists and were unable to block 
calcium entry through voltage-dependent calcium channels. 
 
Keywords: Triazolopyridines, lithiation reaction, α1-adrenoceptor antagonism, calcium channels 
blockade 
 
 
 
Introduction 
 
Phenylalkylamines and phenylethanolamines are well known cardiovascular agents. Related 
compounds such as benzyltetrahydroisoquinoline and bisbenzyltetrahydroisoquinoline alkaloids 
have the ability to block calcium channels and/or antagonize α1-adrenoceptors, and may have 
applications in the treatment of cardiovascular disorders. Some aporphine alkaloids have been 
also reported to have a relaxant effect on vascular smooth muscle that is also related to their 
capacity to inhibit Ca+2 influx through voltage-operated Ca+2 channels or to block α1-
adrenoceptors.1-4 The search for new compounds with activity in vascular pathologies is an 
interesting challenge, considering that these conditions are the major cause of death in the 
European Community. The idea that 7-arylhydroxymethyltriazolopyridines might be considered 
as structural analogues of the above mentioned compounds led us to synthesize a series of these 
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triazolopyridine derivatives and to carry out a preliminary evaluation of them as cardiovascular 
agents. 
 
 
Results and Discussion 
 
A. Chemistry 
In the context of our work on synthesis and reactivity of [1,2,3]triazolo[1,5-a]pyridines 1 and 2,5 
we have studied lithiation reactions that are regioselective at the 7 position. The 7-lithio 
derivatives are formed at –40ºC and can be trapped by electrophiles. We have now used aryl 
aldehydes as electrophiles and have synthesized the new 7-arylhydroxymethyltriazolopyridines 
4a-d in addition to the previously known 3a-c.6 
 
N N
N
R
1, R=H
2, R=CH3
    1) LDA/THF, -40oC
2) ArCHO N N
N
R
CR'OHAr
3a, R=R'=H, Ar=p-MeOPh
3b, R=R'=H, Ar=p-NO2Ph
3c, R=H, R'=Ar=Ph
4a, R=CH3, R'=H, Ar=Ph
4b, R=CH3, R'=H, Ar=m-MeOPh
4c, R=CH3, R'=H, Ar=p-MeOPh
4d, R=CH3, R'=H, Ar=2-Pyridyl  
 
B. Biology 
The activity of compounds 3a-c and 4a-d as relaxants of vascular smooth muscle was tested in 
isolated aortic rings precontracted by noradrenaline in order to determinate whether any of the 
compounds show activity as antagonists of the α1–adrenoceptors present in this tissue and 
stimulated by the noradrenaline. Addition of 10 µM noradrenaline in Krebs solution induced a 
sustained contractile response in the intact rat aortic rings (753.8 ± 78.5 mg; n= 28). Compounds 
3a-c and 4a-d were added in cumulative concentrations (0.0001 µM – 100 µM) to the contracted 
tissue, but changes in the tone were not observed (n = 4 for each compound). The lack of a 
relaxant action excludes the possibility that these compounds act as α1–adrenoceptor antagonists. 
In another set of experiments, addition of depolarising solution (KCl 80mM) to aortic rings 
induced a sustained contractile response in the absence of endothelium (658.8 ± 66.7 mg; n=28). 
In these conditions, opening of voltage-sensitive calcium channels and calcium entry promotes 
this contractile response. Subsequent addition of compounds 3a-c or 4a-d in cumulative 
concentrations (0.0001 µM – 100 µM), once the contractile plateau induced by depolarising 
solution had been reached, did not modify the tone (n = 4 for each compound), thus suggesting 
that none of the compounds tested can block calcium entry through voltage-dependent calcium 
channels.  
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Experimental Section 
 
A. Chemistry 
General Procedures. Melting points were determined on a Kofler heated stage and are 
uncorrected. NMR spectra were recorded on a Bruker AC250 instrument at 250 MHz (1H) or 
62.5 MHz (13C) in CDCl3 as solvent. HRMS (EI) were recorded on a VG Autospec Trio 1000 
(Fisons) instrument. Infrared spectra were recorded in KBr discs on a Bio-Rad FTS-7. 
 
4-Methoxyphenyl-[1,2,3]triazolo[1,5-a]pyridin-7-ylmethanol 3a, 4-nitrophenyl[1,2,3] 
triazolo[1,5-a]pyridin-7-ylmethanol 3b and diphenyl-[1,2,3]triazolo[1,5-a]pyridin-7-yl 
methanol 3c. Prepared as described.6 
 
General procedure for lithiation of 3-methyl-[1,2,3]triazolo[1,5-a]pyridine 2 
A solution of n-butyllithium in hexane (2.4mL, 1.6M) was added to diisopropylamine (0.53mL), 
freshly distilled from KOH, at -40ºC under argon. A solution of 3-methyl-[1,2,3]triazolo[1,5-
a]pyridine 2 (0.5g) in anhydrous THF was added with stirring. A deep red colour developed. The 
mixture was kept at -40ºC for 6h. Treatment with an equimolar amount of the co-reagent 
changed the colour to yellow. The reaction mixture was left at room temperature overnight, and 
quenched with a saturated aqueous solution of ammonium chloride. Extraction with 
dichloromethane gave, after drying and evaporation of the organic solvent, a residue which was 
purified by chromatography over silica gel. The conditions of the purification are given for each 
compound. 
Phenyl-3-methyl[1,2,3]triazolo[1,5-a]pyridin-7-ylmethanol (4a). The co-reagent was 
benzaldehyde (0.39g). Elution with ethyl acetate/hexane (1:1) gave a white solid identified as 4a 
(50% yield). Mp 165-166 ºC (AcOEt/hexane). HRMS found M+ 239.1063; C14H13N3O requires 
239.1058. νmax (KBr) (cm-1) 3300-3200 (broad, OH), 1650-1600 (C=C). 1H NMR δ 7.52-7.47 
(m, 3H), 7.35-7.27 (m, 3H), 7.07 (dd, J1= 6.9, J2= 8.8Hz, 1H), 6.56 (d, J= 6.9Hz, 1H), 6.43 (d, 
JCHOH= 4.0Hz, 1H), 4.08 (d, JCHOH= 4.0Hz, 1H), 2.55 (s, 3H). 13C NMR δ 139.88 (C), 138.60 
(C), 134.74 (C), 132.03 (C), 128.48 (2 CH), 128.36 (2 CH), 127.13 (CH), 124.04 (CH), 116.38 
(CH), 112.94 (CH), 71.73 (CH), 10.31 (CH3). MS m/z (%), 239 (53), 211 (100), 194 (12), 134 
(9), 104 (55), 77 (75).  
3-Methoxyphenyl-3-methyl[1,2,3]triazolo[1,5-a]pyridin-7-ylmethanol (4b). The co-reagent 
was m-anisaldehyde (0.51g). Elution with ethyl acetate/hexane (1:2) gave a yellow solid 
identified as 4b (70% yield). Mp 140-141 ºC (CHCl3/hexane). HRMS found M+ 269.1158; 
C15H15N3O2 requires 269.1164. νmax (KBr) (cm-1) 3300-3200 (broad, OH), 1600 (C=C). 1H NMR 
δ 7.57 (d, J= 8.8Hz, 1H), 7.30 (dd, J1= 8.8, J2= 7.0Hz, 1H), 7.17-7.08 (m, 3H), 6.89 (dd, J1= 2.0, 
J2= 7.5Hz, 1H), 6.64 (d, J= 7.0Hz, 1H), 6.47 (s, 1H, CHOH ), 5.10 (br s, 1H, CHOH), 3.80 (s, 
3H, OCH3), 2.62 (s, 3H). 13C NMR δ 159.69 (C), 140.32 (C), 139.84 (C), 134.62 (C), 131.95 
(C), 129.40 (CH), 124.02 (CH), 119.38 (CH), 116.27 (CH), 113.85 (CH), 112.88 (CH), 112.54 
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(CH), 71.01 (CH), 55.15 (CH3), 10.23 (CH3). MS m/z (%), 269 (57), 241 (84), 224 (42), 198 
(24), 134 (100), 104 (68), 77 (58).  
4-Methoxyphenyl-3-methyl[1,2,3]triazolo[1,5-a]pyridin-7-ylmethanol (4c). The co-reagent 
was p-anisaldehyde (0.51g). Elution with ethyl acetate/hexane (2:3) gave a white solid identified 
as 4c (70% yield). Mp 152-154 ºC (AcOEt/hexane). HRMS found M+ 269.1123; C15H15N3O2 
requires 269.1164. νmax (KBr) (cm-1) 3300-3200 (broad, OH), 1600 (C=C). 1H NMR δ 7.46 (d, 
J= 8.8Hz, 1H), 7.38 (d, J= 7.9Hz, 2H), 7.09 (dd, J1= 8.8, J2= 7.0Hz, 1H), 6.80 (d, J= 7.9Hz, 2H), 
6.68 (d, J= 7.0Hz, 1H), 6.38 (s, 1H, CHOH ), 4.88 (br s, 1H, CHOH), 3.71 (s, 3H, OCH3), 2.51 
(s, 3H). 13C NMR δ 159.50 (C), 140.23 (C), 134.29 (C), 131.27 (C), 130.81 (C), 128.42 (2 CH), 
124.01 (CH), 116.17 (CH), 113.80 (2 CH), 112.57 (CH), 70.83 (CH), 55.18 (OCH3), 10.26 
(CH3). MS m/z (%), 269 (75), 241 (74), 240 (43), 224 (29), 212 (100), 198 (33), 134 (30), 104 
(48), 77 (44).  
2-Piridyl-3-methyl[1,2,3]triazolo[1,5-a]pyridin-7-ylmethanol (4d). The co-reagent was 2-
pyridylcarbaldehyde (0.45g). Elution with ethyl acetate/hexane (1:3) gave a white solid 
identified as 4d (30% yield). Mp 113-115 ºC (CH2Cl2/hexane). HRMS found M+ 240.1011; 
C13H12N4O requires 240.1011. νmax (KBr) (cm-1) 3300-3200 (broad, OH), 1600 (C=C). 1H NMR 
δ 8.45 (d, J= 4.7Hz, 1H), 7.77 (d, J= 7.7Hz, 1H), 7.56 (dd, J1= J2= 7.7Hz, 1H), 7.47 (d, J= 8.8Hz, 
1H), 7.13 (dd, J1= 7.7, J2= 4.7Hz, 1H), 7.11 (dd, J1= 8.8, J2= 6.6Hz, 1H), 6.98 (d, J= 6.6Hz, 1H), 
6.60 (s, 1H, CHOH ), 5.77 (br s, 1H, CHOH), 2.53 (s, 3H). 13C NMR δ 157.44 (C), 148.32 (C), 
139.44 (C), 137.06 (CH), 134.59 (C), 132.07 (CH), 124.13 (CH), 123.31 (CH), 121.96 (CH), 
116.18 (CH), 112.43 (CH), 70.01 (CH), 10.32 (CH3). MS m/z (%), 240 (21), 212 (73), 195 (100), 
169, (8), 134 (57), 104 (35), 77 (14).  
 
B. Biological Evaluation 
Wistar rats of both sexes, weighing 200-220g were decapitated and the thoracic aorta was 
isolated. The connective tissue was removed and the vessels were cut into rings of about 5 mm in 
length which were suspended in a 10 ml organ bath containing Krebs-bicarbonate solution 
(KBS), maintained at 37ºC and gassed with 95% O2 and 5% CO2. An initial load of 1 g was 
applied and maintained throughout a 75-90 min equilibration period. Tension was recorded 
isometrically on a polygraph (Grass M7) via force-displacement transducers (Grass FT03). KBS 
had the following composition (mM): NaCl 118, KCl 4.75, CaCl2 1.8, MgCl2 1.2, KH2PO4 1.2, 
NaHCO3 25 and glucose 11. For experiments with Ca
2+-free solution CaCl2 was omitted and 
EDTA (0.1 mM) was added. Depolarizing solution, 80mM, was prepared by equimolar 
substitution of NaCl by KCl in the Krebs solution. Endothelium-denuded aortic rings were 
prepared by rubbing the entire intimal surface. To test for the presence of vascular endothelium, 
acetylcholine (100 µM) was added to preparations pre-contracted with noradrenaline (1 µM).7 
Acetylcholine-induced-relaxation was expressed as a percentage of the maximum increase in 
tension obtained by NA addition. Segments with relaxant responses lower than 20% were 
considered as endothelium-denuded preparations. Concentration-response relaxation curves were 
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obtained by addition of cumulative concentrations of each compound to vascular rings pre-
contracted by noradrenaline (1 µM) or depolarizing solution.1  
(-)-Noradrenaline bitartrate was from Sigma, St. Louis MO, U.S.A.; other reagents were of 
analytical grade. Compounds 3a-c and 4a-d were dissolved in ethanol and diluted in deionized 
water. The other drugs were dissolved in deionized water. All solutions were prepared daily and 
the pH was adjusted to 7.0. 
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